Novo Nordisk Expects Outlook FY Adjusted Revenue Growth -6 To 0%; Q2 Adj Sales Up 7% At CER; Adj Operating Profit Up 11% At CER; Raises 2026 Adj Sales, Operating Profit Outlook To 0% To -6% At Cer; Improved Outlook Is Driven By Increased Expectations For Glp-1 Product Sales

Benzinga · 1d ago

Novo Nordisk today announced adjusted sales and adjusted operating profit for the second quarter of 2026 and raised 2026 full-year adjusted sales and adjusted operating profit outlook at CER.